Preclinical Imaging

临床前成像

• 批准号: 7714431
• 负责人: RICHARD V MAZURCHUK
• 金额: $ 5.48万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-28 至 2013-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7714431
• 关键词: Angiogenesis Inhibitors; Animal Disease Models; Animals; Area; Arts; Basic Science; Biotechnology; Blood Vessels; Boston; Budgets; Buffaloes; Cancer Center Support Grant; Cancer Detection; Chemicals; Clinical Research; Compatible; Computer software; Custom; Data; Data Analyses; Data Set; Development; Diffusion; Discipline of Nuclear Medicine; Drug Delivery Systems; Drug Kinetics; Electronics; Faculty; Fostering; Gadolinium DTPA; Gadopentetate Dimeglumine; Goals; Hour; Housing; Human; Image; Image Analysis; Image Cytometry; Imagery; Imaging Techniques; Imaging technology; Knowledge; Label; Laboratories; Lanthanoid Series Elements; Life; Lysine; Magnetic Resonance; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant Neoplasms; Maps; Methodology; Methods; Molecular; Molecular Weight; Multimodal Imaging; Neoplasms in Vascular Tissue; Optics; Other Resources; Permeability; Pharmacologic Substance; Phenotype; Physiology; Protocols documentation; Range; Recruitment Activity; Research; Research Personnel; Resolution; Resources; Screening procedure; Sensitivity and Specificity; Services; Spectrum Analysis; Standards of Weights and Measures; Stress Tests; System; Techniques; Therapeutic; Three-dimensional analysis; Time; Training; Transgenic Mice; Treatment Efficacy; Tumor Oxygenation; Universities; Validation; Visual; Week; base; blood oxygen level dependent; cohort; cost; data acquisition; day; design; digital; fluorescence imaging; image processing; in vivo; instrumentation; interest; intravital microscopy; magnetic field; member; new technology; novel; optical imaging; pharmacodynamic model; pre-clinical; programs; research study; response; tool; tumor

The goal of RPCI's Preclinical Imaging Resource (PIR) is to advance small animal imaging methodology at the molecular, cellular and biosystem level. This is accomplished by facilitating development of novel basic science and clinical research, promoting advances in biotechnology, fostering development of new Pharmaceuticals and assessing in vivo drug delivery and therapeutic efficacy. The PIR currently offers customized magnetic resonance (MR) protocols designed to answer specific questions related to: (i) cancer detection, (ii) tumor vascular function, (iii) therapeutic response, (iv) animal phenotyping and (v) pharmacokinetic /pharmacodynamic modeling. In addition, the Resource provides whole-body fluorescence imaging of live animals and facilitates collaborative microPET research in conjunction with the University at Buffalo (UB). The aim is to provide readily available access and training to noninvasive, state-of-the-art in vivo imaging technologies at an affordable cost to CCSG members. The PIR is available 24 hours/day, 7 days/week. Three general types of MR services are offered: (a) instrumentation and expertise to acquire high resolution (< 50 urn2 in-plane spatial and < 100 ms temporal) heteronuclear imaging and spectroscopy data, (b) expertise and software for quantitative image analysis and (c) visualization of 2D and 3D data sets for probing structural/functional relationships. MR instrumentation includes a 4.7 T wide bore (33 cm) magnet incorporating Bruker's Avance platform with ParaVision¿ 4.0 OS, shielded Accustar gradients and digital system electronics. The MR system represents the highest magnetic field strength scanner available within 200 miles of RPCI. Recently expanded services include whole body in vivo optical and multispectral fluorescence imaging. Intravital Microscopy (IVM) using a MR compatible window chamber is also available for fluorescence imaging with MR validation. Data acquisition, hardcopy, display, qualitative/quantitative analysis and 3D renderings of digitally acquired data sets are offered as chargeback services. The Resource is used by five programs and 99% of users are CCSG members. $65,218 in CCSG support is requested, representing 12% of the total operating budget.

RPCI的临床前成像资源（PIR）的目标是推进小动物成像 分子、细胞和生物系统水平的方法学。这是通过促进发展来实现的 新的基础科学和临床研究，促进生物技术的进步， 新药物和评估体内药物递送和治疗功效。PIR目前提供 定制的磁共振（MR）协议，旨在回答与以下相关的特定问题：（i）癌症 检测，（ii）肿瘤血管功能，（iii）治疗反应，（iv）动物表型和（v） 药代动力学/药效学建模。此外，该资源提供全身荧光 活体动物的成像，并促进合作microPET研究与大学在 布法罗（UB）。其目的是提供随时可用的非侵入性、最先进技术的获取和培训 以CCSG成员负担得起的成本提供活体成像技术。PIR是24小时/天，7 天/周。 提供三种一般类型的磁共振服务：（a）仪器和专业知识，以获得高 分辨率（< 50 μ m 2的平面内空间和< 100 ms的时间）的异质结成像和光谱数据， (b)定量图像分析的专业知识和软件，以及（c）2D和3D数据集的可视化， 探索结构/功能关系。MR仪器包括4.7 T宽孔（33 cm）磁体 将Bruker的Avance平台与ParaVision <$4.0操作系统相结合， 电子系统MR系统代表了现有的最高磁场强度扫描仪， 200英里的RPCI。最近扩展的服务包括全身活体光学和多光谱 荧光成像还提供使用MR兼容窗室的活体显微镜检查（IVM） 用于MR验证的荧光成像。数据采集、硬拷贝、显示、定性/定量 对数字采集的数据集进行分析和3D渲染，作为收费服务提供。 该资源被五个项目使用，99%的用户是CCSG成员。CCSG 65，218美元 要求提供的支助占业务预算总额的12%。